MTOR: A pathogenic signaling pathway in developmental brain malformations

Trends in Molecular Medicine

Volumn 17, Issue 12, 2011, Pages 734-742

  Crino, Peter B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MAMMALIAN TARGET OF RAPAMYCIN; REGULATOR PROTEIN;

BRAIN DEVELOPMENT; BRAIN MALFORMATION; EPILEPTOGENESIS; GENE EXPRESSION; HUMAN; LOSS OF FUNCTION MUTATION; NEUROBIOLOGY; NEUROPATHOLOGY; NEUROSCIENCE; NONHUMAN; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; AUTISTIC DISORDER; BIOLOGICAL MARKERS; CEREBRAL CORTEX; EPILEPSY; HUMANS; MALFORMATIONS OF CORTICAL DEVELOPMENT; MICE; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; PROTEINS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84855958205     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.07.008     Document Type: Review

References (93)

1. Rogeveen J. The Journal of Jacob Roggeveen 1970, Oxford University Press. A. Sharp (Ed.).
2. Sneader W. Drug Discovery: A History 2005, John Wiley Press.
3. Crino P.B., et al. Medical progress: tuberous sclerosis complex. New Engl. J. Med. 2006, 355:1345-1356.
4. Baybis M., et al. Activation of the mTOR cascade distinguishes cortical tubers from focal cortical dysplasia. Ann. Neurol. 2004, 56:478-487.
5. Miyata H., et al. Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis. Ann. Neurol. 2004, 56:510-519.
6. Wang X., Proud C.G. mTORC1 signaling: what we still don't know. J. Mol. Cell Biol. 2010, 1:1-16.
7. Zoncu R., et al. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.
8. Potter C.J., et al. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001, 105:357-368.
9. Gao X., Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001, 15:1383-1392.
10. Loewith R., et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 2002, 10:457-468.
11. Orlova K.A., Crino P.B. The tuberous sclerosis complex. Ann. N.Y. Acad. Sci. 2010, 1184:87-105.
12. Inoki K., et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17:1829-1834.
13. Garami A., et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 2003, 11:1457-1466.
14. Ma L., et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193.
15. Lee D.F., et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007, 130:440-455.
16. Potter C.J., et al. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 2002, 4:658-665.
17. Manning B.D., et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol. Cell 2002, 10:151-162.
18. Hahn-Windgassen A., et al. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem. 2005, 280:32081-32089.
19. Jaeschke A., et al. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol. 2002, 159:217-224.
20. Ruvinsky I., Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem. Sci. 2006, 31:342-348.
21. Ruvinsky I., et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 2005, 19:2199-2211.
22. Gingras A.C., et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001, 15:2852-2864.
23. Chan J.A., et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J. Neuropathol. Exp. Neurol. 2004, 63:1236-1242.
24. Shima H., et al. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 1998, 17:6649-6659.
25. Gingras A.C., et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 1998, 12:502-513.
26. Huang J., Manning B.D. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 2008, 412:179-190.
27. Yu Y., et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011, 332:1322-1326.
28. Hsu P.P., et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332:1317-1322.
29. Harrington L.S., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004, 166:213-223.
30. Shah O.J., et al. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 2004, 14:1650-1656.
31. Krsek P., et al. Different features of histopathological subtypes of pediatric focal cortical dysplasia. Ann. Neurol. 2008, 63:758-769.
32. Blümcke I., et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 2011, 52:158-174.
33. Crino P.B., et al. Neurodevelopmental disorders as a cause of seizures: neuropathologic, genetic, and mechanistic considerations. Brain Pathol. 2002, 12:212-233.
34. Wong M. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia 2008, 49:8-21.
35. Crino P.B., et al. Embryonic neuronal markers in tuberous sclerosis: single cell molecular pathology. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:14152-14157.
36. Thom M., et al. Mcm2 labelling of balloon cells in focal cortical dysplasia. Neuropathol. Appl. Neurobiol. 2005, 31:580-588.
37. Yasin S.A., et al. Balloon cells in human cortical dysplasia and tuberous sclerosis: isolation of a pathological progenitor-like cell. Acta Neuropathol. 2010, 120:85-96.
38. Orlova K.A., et al. Early progenitor cell marker expression distinguishes type II from type I focal cortical dysplasias. J. Neuropath. Exp. Neurol. 2010, 69:850-863.
39. Ljungberg M.C., et al. Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann. Neurol. 2006, 60:420-429.
40. White R., et al. Differential transcription of neurotransmitter receptor subunits and uptake sites in giant cells and dysplastic neurons in cortical tubers. Ann. Neurol. 2001, 49:67-78.
41. Schick V., et al. Differential Pi3K-pathway activation in cortical tubers and focal cortical dysplasias with balloon cells. Brain Pathol. 2007, 17:165-173.
42. Aronica E., et al. Co-expression of cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly. Acta Neuropathol. (Berl.) 2007, 114:287-293.
43. Samadani U., et al. Differential gene expression in neurons and astrocytes in ganglioglioma. Epilepsia 2007, 48:646-653.
44. Crino P.B. Focal brain malformations: a spectrum of disorders along the mTOR cascade. Novartis Found. Symp. 2007, 288:260-272. discussion 272-281.
45. Puffenberger E.G., et al. Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5. Brain 2007, 130:1929-1941.
46. Lizcano J.M., et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23:833-843.
47. Shaw R.J., et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-99.
48. Orlova K.A., et al. STRADα deficiency results in aberrant mTORC1 signaling during corticogenesis. J. Clin. Invest. 2010, 120:1591-1602.
49. Hentges K.E., et al. mTOR is required for proliferation and patterning during embryonic development in the mouse. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13796-13801.
50. Jossin Y., et al. Reelin signals through phosphatidylinositol 3-kinase and Akt to control cortical development and through mTor to regulate dendritic growth. Mol. Cell Biol. 2007, 27:7113-7124.
51. Kwon C.H., et al. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12923-12928.
52. Fraser M.M., et al. Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res. 2004, 64:7773-7779.
53. Ljungberg M.C., et al. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis. Model Mech. 2009, 2:389-398.
54. Ehninger D., Silva A.J. Rapamycin for treating tuberous sclerosis and autism spectrum disorders. Trends Mol. Med. 2011, 17:78-87.
55. Onda H., et al. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol. Cell Neurosci. 2002, 21:561-574.
56. Uhlmann E.J., et al. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann. Neurol. 2002, 52:285-296.
57. Meikle L., et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J. Neurosci. 2007, 27:5546-5558.
58. Way S.W., et al. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis. Hum. Mol. Genet. 2009, 18:1252-1265.
59. Tavazoie S.F. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat. Neurosci. 2005, 8:1727-1734.
60. Feliciano D.M., et al. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. J. Clin. Invest. 2011, 121:1596-1607.
61. Talos D.M., et al. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann. Neurol. 2008, 63:454-465.
62. Aronica E., et al. Expression and cell distribution of group I and group II metabotropic glutamate receptor subtypes in taylor-type focal cortical dysplasia. Epilepsia 2003, 44:785-795.
63. Ehninger D. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat. Med. 2008, 14:843-848.
64. Crino P.B., et al. Expression of glutamate and GABA A receptor subunit genes is distinct in dysplastic and heterotopic neurons. Neurology 2001, 57:904-913.
65. Baybis M., et al. Altered expression of neurotransmitter receptor subunit and uptake site mRNAs in hemimegalencephaly. Epilepsia 2004, 45:1517-1524.
66. Meikle L., et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 2008, 28:5422-5432.
67. Zeng L.H., et al. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum. Mol. Genet. 2011, 20:445-454.
68. Zeng L.H., et al. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol. 2008, 63:444-453.
69. Zeng L.H., et al. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J. Neurosci. 2009, 29:6964-6972.
70. Huang X., et al. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol. Dis. 2010, 40:193-199.
71. Buckmaster P.S., et al. Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J. Neurosci. 2009, 29:8259-8269.
72. Daoud D., et al. Rapamycin: brain excitability studied in vitro. Epilepsia 2007, 48:834-836.
73. Rüegg S., et al. Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res. 2007, 77:85-92.
74. Wang Y., et al. A role for the mTOR pathway in surface expression of AMPA receptors. Neurosci. Lett. 2006, 401:35-39.
75. Li N., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
76. Waltereit R., et al. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. J. Neurochem. 2006, 96:407-413.
77. Schindler G., et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011, 121:397-405.
78. Narayanan U., et al. S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. J. Biol. Chem. 2008, 283:18478-18482.
79. Sharma A., et al. Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 2010, 30:694-702.
80. Krueger D.A., et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 2010, 363:1801-1811.
81. Mathern G.W., et al. Neurons recorded from pediatric epilepsy surgery patients with cortical dysplasia. Epilepsia 2000, 41(Suppl. 6):S162-S167.
82. Dorfman J., Macara I.G. STRADalpha regulates LKB1 localization by blocking access to importin-alpha, and by association with Crm1 and exportin-7. Mol. Biol. Cell 2008, 19:1614-1626.
83. Zeqiraj E., et al. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 2009, 326:1707-1711.
84. Matsuki T., et al. Reelin and stk25 have opposing roles in neuronal polarization and dendritic Golgi deployment. Cell 2010, 143:826-836.
85. Nie D., et al. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat. Neurosci. 2010, 13:163-172.
86. Choi Y., et al. Tuberous sclerosis complex proteins control axon formation. Genes Dev. 2008, 22:2485-2495.
87. Lamb R.F. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat. Cell Biol. 2000, 2:281-287.
88. Haddad L.A., et al. The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton. J. Biol. Chem. 2002, 277:44180-44186.
89. Goncharova E., et al. TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J. Cell Biol. 2004, 167:1171-1182.
90. Barnes A.P., et al. LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. Cell 2007, 129:549-563.
91. Kishi M., et al. Mammalian SAD kinases are required for neuronal polarization. Science 2005, 307:929-932.
92. Shelly M., et al. LKB1/STRAD promotes axon initiation during neuronal polarization. Cell 2007, 129:565-577.
93. Amato S., et al. AMP-activated protein kinase regulates neuronal polarization by interfering with PI 3-kinase localization. Science 2011, 332:247-251.